ByLisaU (@ByLisaU) header
ByLisaU (@ByLisaU) profile picture

ByLisaU

@ByLisaU

Freelance pharma and biotech editor/writer, interested in health inequality, pharma AI and drug discovery and development. DM or email me at [email protected]

 UK
Joined June 2009
  • Tweets1.4K
  • Following527
  • Followers941
45Media
Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)Photo by ByLisaU (@ByLisaU)
Can Enhertu push on the HER2-low door once again? My quick take for @apexonco oncologypipeline.com/apexonc… $AZN $DSNKY
Enhertu pushes on the HER2-low door once again

Enhertu pushes on the HER2-low door once again

Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

apexonco.com
4
1
6
8,613
Good timing for my Pdufa story given the $BIIB $RETA news, Zuranolone's decision is due 5 Aug. Check out the full August table here👉evaluate.com/vantage/article… #FDA $SAGE $ALPMY $APLS $REGN $PFE $NVS #ASRS2023
Image from Joanne Fagg (@ByJoFagg)
1
2
9
4,492
Biogen's Chris Viehbacher $BIIB makes big $7.3bn M&A move for $RETA, but is it too pricey? Mine and @EdwinElmhirst's take via @evaluatevantage evaluate.com/vantage/article…
1
2
1,519
The $LLY vs $NVO grudge match continues, with the US group winning another couple of rounds in obesity evaluate.com/vantage/article…
Image from Elizabeth Cairns (@ByLizC)
4
1
12
8,066
Investors unimpressed at Viehbacher's attempts to clean house as $BIIB shares fall. My quick take via @Evaluatevantage evaluate.com/vantage/article…
1
1
959
And now the $FGEN CEO is out. nitter.gq/evaluatevantage/status…
2
4
6
8,125
The urticaria pipeline is pretty busy, but can anyone beat Xolair? Here's a look at the late-stage projects due to report clinical data in the next six to 12 months 👉evaluate.com/vantage/article… $NVS $RHHBY $SNY $REGN $AMGN $AZN $ALLK $CLDX
2
3
1,408
Another Q2 $NVS discontinuation: MBL949, now revealed to have been a GDF-15 (inhibitor?) for obesity. Remember company had highlighted this as an asset for investors to watch in Q1, just 3 mths ago
Image from Jacob Plieth (@JacobPlieth)
2
3
18
9,794
$ABOS's new amyloid approach impresses at #AAIC2023, but how differentiated will it turn out to be? I interviewed the company for @evaluatevantage evaluate.com/vantage/article…
1
3
1
12
2,691
$LLY downplays tau testing needs as full donanemab phase 3 data presented at #AAIC2023. My take via @evaluatevantage evaluate.com/vantage/article…
1
8
11
4,262
$BBIO turns a failure into a success; might partners come knocking? evaluate.com/vantage/article…
3
3
1,784
The year is 2040. Every incretin known to man has been combined into a weight loss drug. 100% weight loss. It’s a euthanasia drug. Degrades your bones and your organs. Life is good.
7
6
1
53
6,471
$QURE hails AMT-130 efficacy, but that's questionable, and the Huntington’s gene therapy has other, more fundamental problems. Via @evaluatevantage -> evaluate.com/vantage/article…
5
11
6,214
ICYMI all the key FDA Pdufa and adcom dates this month: evaluate.com/vantage/article… This week: 📣Beyfortus (nirsevimab) RSV adcom tomorrow $SNY $AZN 📣Leqembi confirmatory study adcom 9 June $EASLY $ESALF $BIIB
1
1
1,104
And now Dizal's data with sunvozertinib (the EGFR star of #Asco21) in pivotal Wukong6 trial in 2L exon20 ins. Note responses in post-Rybrevant patients, via Mengzhao Wang: $AZN $JNJ $TAK #Asco23
Image from Jacob Plieth (@JacobPlieth)
1
7
27
12,081
The search is on for early signals in front-line NSCLC for datopotamab, the Trop2 ADC that is already in three pivotal trials. My take on the #ASCO23 data: evaluate.com/vantage/article… $AZN $DSNKY
Image from Amy Brown (@ByAmyBrown)
8
13
6,838
#ASCO23 Bicara's impressive data in head and neck cancer (48% ORR, 65% in HPV negative disease) potential beats Keytruda, and has the private group making pivotal plans. I spoke to CEO Claire Mazumdar: evaluate.com/vantage/article… $MRK
3
10
2
28
20,701
Replying to @JacobPlieth @PinkSheetSutter
As expected then: FDA expands $AZN $MRK Lynparza use to prostate cancer - but only in Brca +ves astrazeneca.com/media-centre…

Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castrat...

astrazeneca.com
4
519
Another of $PFE's haemophilia candidates succeeds in phase 3 - but can it get past the regulators? evaluate.com/vantage/article…
Image from Elizabeth Cairns (@ByLizC)
4
1
3
4,725
Tigit FTW! First take on some #Asco23 abstracts, plus what's in the late-breakers? Via @evaluatevantage -> evaluate.com/vantage/article… $ITOS $RCUS $CGEN $NVS $IMGN $AZN
3
10
2
24
14,496
Load more